As of 2025-11-09, the EV/EBITDA ratio of Travere Therapeutics Inc (TVTX) is -87.84. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TVTX's latest enterprise value is 3,083.23 mil USD. TVTX's TTM EBITDA according to its financial statements is -35.10 mil USD. Dividing these 2 quantities gives us the above TVTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 15.4x | 15.2x |
| Forward P/E multiples | 14.0x - 20.3x | 15.5x |
| Fair Price | (8.14) - (8.33) | (8.29) |
| Upside | -125.2% - -125.8% | -125.6% |
| Date | EV/EBITDA |
| 2025-11-05 | -91.34 |
| 2025-11-04 | -92.38 |
| 2025-11-03 | -93.40 |
| 2025-10-31 | -95.00 |
| 2025-10-30 | -81.01 |
| 2025-10-29 | -81.85 |
| 2025-10-28 | -81.41 |
| 2025-10-27 | -81.31 |
| 2025-10-24 | -76.97 |
| 2025-10-23 | -77.20 |
| 2025-10-22 | -75.50 |
| 2025-10-21 | -76.31 |
| 2025-10-20 | -76.54 |
| 2025-10-17 | -75.09 |
| 2025-10-16 | -75.57 |
| 2025-10-15 | -73.90 |
| 2025-10-14 | -72.09 |
| 2025-10-13 | -72.25 |
| 2025-10-10 | -69.60 |
| 2025-10-09 | -71.92 |
| 2025-10-08 | -72.25 |
| 2025-10-07 | -70.47 |
| 2025-10-06 | -72.07 |
| 2025-10-03 | -68.28 |
| 2025-10-02 | -67.22 |
| 2025-10-01 | -68.67 |
| 2025-09-30 | -66.41 |
| 2025-09-29 | -66.76 |
| 2025-09-26 | -69.96 |
| 2025-09-25 | -68.20 |
| 2025-09-24 | -67.70 |
| 2025-09-23 | -67.24 |
| 2025-09-22 | -70.29 |
| 2025-09-19 | -68.82 |
| 2025-09-18 | -67.14 |
| 2025-09-17 | -65.77 |
| 2025-09-16 | -63.54 |
| 2025-09-15 | -64.14 |
| 2025-09-12 | -65.31 |
| 2025-09-11 | -69.20 |
| 2025-09-10 | -75.06 |
| 2025-09-09 | -60.67 |
| 2025-09-08 | -59.55 |
| 2025-09-05 | -60.67 |
| 2025-09-04 | -59.42 |
| 2025-09-03 | -55.51 |
| 2025-09-02 | -51.80 |
| 2025-08-29 | -50.15 |
| 2025-08-28 | -50.66 |
| 2025-08-27 | -50.00 |